FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Invega Not Withdrawn Due to Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that Janssen Pharmaceuticals Invega (paliperidone) extended-release tablet was not withdra...

Janssens TB Drug Converted to Full Approval

[ Price : $8.95]

FDA converts Janssens Sirturo (bedaquiline) from accelerated to traditional approval following a determination that a confirmatory...

Switching Studies for Interchangeable Biosimilars Guide

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Considerations in Demonstrating Interchangeability With a R...

Guide on Adulteration when Inspection Refused

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Circumstances That Constitute Delaying, Denying, Limiting, ...

Guide on Human User Safety in Animal Drugs

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Human User Safety in New and Abbreviated New Animal Drug Ap...

Workshop on NDA/BLA Meeting Management Practices

[ Price : $8.95]

FDA announces a 7/22 public workshop on Best Practices for Meeting Management Under PDUFA VII.

Lillys Files Mounjara NDA for Sleep Apnea

[ Price : $8.95]

Eli Lilly says it has submitted an NDA for weight loss therapy Mounjaro (tirzepatide) for treating moderate-to-severe obstructive ...

Lexicon Refiles NDA for Sotagliflozin

[ Price : $8.95]

After receiving a 2019 complete response letter, Lexicon Pharmaceuticals resubmits its NDA for sotagliflozin oral tablets as an ad...

Dj vu: Marks Overrides Reviewers on Duchenne Drug Again

[ Price : $8.95]

CBER director Peter Marks again overrides his Centers review teams in approving a supplemental BLA that expands the approval and c...

Zoll Recalls Ventilators Over Operator Guides

[ Price : $8.95]

Zoll Medical recalls (Class 1) its Zoll 731 Ventilators and their operator and quick reference guides.